On October 9, WUXI XDC fell 3.47% in regular trading, trading at HK$78.95/share, with Turnover of HK$107 million.

The decline was driven by broad weakness across the Life Sciences Tools & Services sector, with peers retreating in tandem: WUXI BIO fell 3.42%, WUXI APPTEC fell 2.39%, INSILICO fell 2.32%, XTALPI fell 3.29%, while GENSCRIPT BIO edged up 0.84%.

Earlier in the session, investors digested a mixed backdrop — recent high-profile institutional activity included Schroders PLC increasing its stake to 5.01% in mid-September, while WUXI APPTEC-affiliated entities trimmed their holdings to 14.14% in late August. Goldman Sachs maintained a Buy rating with a target price of HK$97.90, citing upcoming FDA inspection of the Wuxi manufacturing facility as a key commercialization catalyst.

The company offers comprehensive CRDMO services for antibody-drug conjugates and other bioconjugates across domestic and international markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)